William Blair Issues Optimistic Outlook for Enovis Earnings

Enovis Co. (NYSE:ENOV) – Investment analysts at William Blair boosted their Q1 2025 earnings per share estimates for Enovis in a research report issued to clients and investors on Wednesday, February 26th. William Blair analyst B. Vazquez now forecasts that the company will post earnings per share of $0.75 for the quarter, up from their prior forecast of $0.70. The consensus estimate for Enovis’ current full-year earnings is $2.79 per share. William Blair also issued estimates for Enovis’ Q2 2025 earnings at $0.70 EPS, Q3 2025 earnings at $0.76 EPS, FY2025 earnings at $3.16 EPS, Q1 2026 earnings at $0.82 EPS, Q2 2026 earnings at $0.77 EPS, Q3 2026 earnings at $0.84 EPS, Q4 2026 earnings at $1.05 EPS and FY2026 earnings at $3.48 EPS.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $560.98 million for the quarter, compared to analysts’ expectations of $555.14 million.

Separately, Needham & Company LLC decreased their price target on shares of Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday.

Enovis Trading Down 4.6 %

NYSE:ENOV opened at $38.16 on Friday. The company has a market capitalization of $2.17 billion, a PE ratio of -17.42 and a beta of 1.94. Enovis has a 52-week low of $38.08 and a 52-week high of $63.96. The stock’s 50 day moving average price is $44.90 and its 200 day moving average price is $44.34. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Aster Capital Management DIFC Ltd purchased a new stake in Enovis in the 4th quarter valued at approximately $29,000. Quadrant Capital Group LLC boosted its stake in shares of Enovis by 53.0% in the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company’s stock valued at $30,000 after buying an additional 239 shares in the last quarter. UMB Bank n.a. grew its holdings in Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after acquiring an additional 437 shares during the period. Pinnacle Bancorp Inc. raised its position in Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after acquiring an additional 300 shares in the last quarter. Finally, Quarry LP raised its position in Enovis by 506.1% in the fourth quarter. Quarry LP now owns 897 shares of the company’s stock worth $39,000 after acquiring an additional 749 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.